8dp0
Structure of p110 gamma bound to the Ras inhibitory nanobody NB7
Structural highlights
Publication Abstract from PubMedPI3Kgamma is a critical immune signaling enzyme activated downstream of diverse cell surface molecules, including Ras, PKCbeta activated by the IgE receptor, and Gbetagamma subunits released from activated GPCRs. PI3Kgamma can form two distinct complexes, with the p110gamma catalytic subunit binding to either a p101 or p84 regulatory subunit, with these complexes being differentially activated by upstream stimuli. Here, using a combination of cryo electron microscopy, HDX-MS, and biochemical assays, we have identified novel roles of the helical domain of p110gamma in regulating lipid kinase activity of distinct PI3Kgamma complexes. We defined the molecular basis for how an allosteric inhibitory nanobody potently inhibits kinase activity through rigidifying the helical domain and regulatory motif of the kinase domain. The nanobody did not block either p110gamma membrane recruitment or Ras/Gbetagamma binding, but instead decreased ATP turnover. We also identified that p110gamma can be activated by dual PKCbeta helical domain phosphorylation leading to partial unfolding of an N-terminal region of the helical domain. PKCbeta phosphorylation is selective for p110gamma-p84 compared to p110gamma-p101, driven by differential dynamics of the helical domain of these different complexes. Nanobody binding prevented PKCbeta-mediated phosphorylation. Overall, this work shows an unexpected allosteric regulatory role of the helical domain of p110gamma that is distinct between p110gamma-p84 and p110gamma-p101 and reveals how this can be modulated by either phosphorylation or allosteric inhibitory binding partners. This opens possibilities of future allosteric inhibitor development for therapeutic intervention. , PMID:37417733[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
| ||||||||||||||||||
